NCT02571036: A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KIT, PDGFR, TIE, CSFR, VEGFR
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have gene alterations in one of the following: KIT, PDGFR (A or B), TIE2, CSF1R, & VEGFR2
Exclusions: Patients with unstable symptomatic central nervous system (CNS) metastases

Up ↑